Company intelligence / Profile preview
Sound
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
Overview
Sound Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing the first regenerative and protective therapies for sensorineural hearing loss and tinnitus. The company's lead candidate, SPI-1005 (ebselen), is a small molecule that mimics the activity of glutathione peroxidase (GPx), a key antioxidant enzyme in the inner ear. SPI-1005 has received FDA Breakthrough Therapy Designation for the treatment of Meniere's disease and is currently in Phase 3 clinical trials. Sound Pharmaceuticals is also exploring SPI-1005 for other neurotologic conditions, including noise-induced hearing loss and ototoxicity, as well as neuropsychiatric disorders.
- Therapeutic areas
- PsychiatryNeurologyOtherInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Sound.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sound.